市場調查報告書
商品編碼
1447638
血流感染檢測市場- 按產品(儀器、試劑和消耗品)、樣本類型(全血、血液培養)、技術(PCR、質譜、原位雜合技術)、最終用途(醫院) - 全球預測,2024 年- 2032 年Bloodstream Infection Testing Market - By Product (Instruments, Reagents & Consumables), Sample Type (Whole Blood, Blood Culture), Technology (PCR, Mass Spectroscopy, In Situ Hybridization), End-use (Hospitals) - Global Forecast, 2024 - 2032 |
在質譜和自動化血液培養系統等診斷技術和儀器進步的推動下,血流感染檢測市場規模從 2024 年到 2032 年將以 4.9% 的CAGR成長。不斷湧現的創新正在提供更快、更準確、更有效率的測試方法,以改善患者的治療結果。此外,醫療保健公司之間合作開發新型檢測解決方案將有助於市場擴張。先進技術與醫療保健領域的協作努力之間的協同作用也將有助於滿足對血流感染準確及時診斷不斷成長的需求。
例如,2023 年 11 月,Oxford Nanopore 和 Day Zero Diagnostics (DZD) 合作創建了一種診斷血流感染的綜合解決方案,血流感染是導致敗血症(一種危及生命的疾病)的主要原因。此次合作也提供了端到端的診斷解決方案,以提高患者的治療效果。
血流感染檢測產業分為樣本類型、技術、最終用途和地區。
根據產品,到 2032 年,儀器領域的市佔率CAGR將達到 4.5%。這是由於擴大採用自動化儀器來更快、更準確地檢測血流感染。血液培養系統和分子診斷平台等儀器可以快速提供結果並改善患者的治療效果。最近,儀器技術不斷進步,例如靈敏度和特異性的增強。對早期和精確診斷的日益重視也將增加對儀器的需求。
到 2032 年,質譜技術領域的血流感染檢測行業將以 4.9% 的CAGR大幅成長。這種成長是由質譜在識別病原體和確定抗生素抗藥性方面的準確性和效率所推動的。質譜分析能夠快速、全面地分析微生物蛋白質,有助於及時做出針對性的治療決策。隨著對精確可靠的感染檢測方法的需求不斷成長,質譜技術的應用不斷增加。此外,臨床實驗室和醫院擴大採用該技術將進一步推動該領域的成長。
由於傳染病負擔日益增加、人們對早期檢測重要性的認知不斷提高以及醫療基礎設施的改善,2024年至2032年亞太地區血流感染檢測行業佔有率的CAGR將達到5.2%。由於中國、印度和日本等國家人口眾多,人們越來越關注醫療保健的進步。此外,對創新診斷技術不斷成長的需求將進一步加強亞太地區作為血流感染檢測市場主要貢獻者的地位。
Bloodstream Infection Testing Market size will grow at 4.9% CAGR from 2024 to 2032, propelled by advancements in diagnostic technologies and instruments like mass spectrometry and automated blood culture systems. Rising innovations are offering faster, more accurate, and efficient testing methods for improving patient outcomes. Additionally, collaborations between healthcare companies for the development of novel testing solutions will contribute to the market expansion. The synergy between advanced technologies and collaborative efforts in the healthcare sector will also help meet the rising demand for precise and timely diagnosis of bloodstream infections.
For instance, in November 2023, Oxford Nanopore and Day Zero Diagnostics (DZD) collaborated to create a comprehensive solution for diagnosing bloodstream infections, a primary contributor to sepsis, a life-threatening condition. This partnership also offered an end-to-end diagnostic solution for enhanced patient outcomes.
The bloodstream infection testing industry is classified into sample type, technology, end-use, and region.
Based on product, the market share from the instruments segment will garner 4.5% CAGR up to 2032. This is due to the increasing adoption of automated instruments for faster and accurate detection of bloodstream infections. Instruments, such as blood culture systems and molecular diagnostic platforms, offer rapid results and improve patient outcomes. Lately, there have been rising advancements in instrument technology, such as enhanced sensitivity and specificity. The growing emphasis on early and precise diagnosis will also add to the demand for instruments.
Bloodstream infection testing industry from the mass spectroscopy technology segment will witness a substantial upswing at 4.9% CAGR through 2032. The growth is driven by the accuracy and efficiency of mass spectrometry in identifying pathogens and determining antibiotic resistance. Mass spectrometry enables rapid and comprehensive analysis of microbial proteins for aiding in timely and targeted treatment decisions. With the growing demand for precise and reliable infection testing methods, the deployment of mass spectroscopy is rising. Moreover, increasing adoption in clinical laboratories and hospitals will further propel the segment growth.
Asia Pacific bloodstream infection testing industry share will register a 5.2% CAGR from 2024 to 2032, owing to the increasing burden of infectious diseases, rising awareness about the importance of early detection, and improving healthcare infrastructure. With the large population in countries like China, India, and Japan, there is a growing focus on healthcare advancements. Additionally, the rising demand for innovative diagnostic technologies will further strengthen Asia Pacific's position as a key contributor in the bloodstream infection testing market.